Acute Hepatitis

Acute hepatitis in veterinary medicine refers to a sudden onset of hepatocellular injury and inflammation, characterized by a rapid elevation of liver enzymes (ALT, AST) and often accompanied by clinical signs such as vomiting, anorexia, and jaundice. The condition can be caused by infectious agents, toxins, drugs, or metabolic disturbances, and may progress to acute liver failure if severe. Acute hepatitis is distinct from chronic hepatitis, which involves persistent inflammation and fibrosis over months to years. The liver's remarkable regenerative capacity allows for recovery if the inciting cause is removed and supportive care is provided, but the condition can be life-threatening if massive necrosis occurs.

The etiologies of acute hepatitis in dogs and cats are diverse. Infectious causes include viral agents such as canine adenovirus type 1 (CAV-1) causing infectious canine hepatitis, feline infectious peritonitis (FIP) virus, and leptospirosis (Leptospira interrogans serovars). Bacterial infections, such as those from ascending biliary tract infections or sepsis, can also cause acute hepatitis. Toxins include xylitol, aflatoxins (from contaminated grains), blue-green algae (microcystins), heavy metals (copper, zinc), and various plants (e.g., cycads, mushrooms like Amanita phalloides). Drug-induced hepatotoxicity is common, with agents such as acetaminophen (paracetamol), carprofen, diazepam, and certain anticonvulsants (phenobarbital, phenytoin) implicated. Metabolic causes include hepatic lipidosis in cats, which can be triggered by anorexia, and copper-associated hepatopathy in dogs (e.g., Bedlington Terriers). Autoimmune and immune-mediated mechanisms may also play a role, though they are less well-defined in acute presentations. In many cases, the exact cause remains idiopathic.

Acute hepatitis can affect dogs and cats of any age, breed, or sex, though certain breeds have genetic predispositions to specific hepatopathies. For example, Bedlington Terriers, West Highland White Terriers, and Doberman Pinschers are prone to copper-associated hepatitis. Leptospirosis is more common in dogs with access to wildlife or contaminated water sources, and has a seasonal peak in late summer and fall. Infectious canine hepatitis is rare in well-vaccinated populations but can occur in unvaccinated dogs. Drug-induced hepatotoxicity is more common in dogs than cats, with certain breeds (e.g., Labrador Retrievers) showing increased sensitivity to drugs like carprofen. Acute hepatitis can occur at any age, but middle-aged to older animals may be more susceptible due to concurrent diseases or polypharmacy. No clear sex predilection exists, though some studies suggest a slight male predominance for leptospirosis.

The pathophysiology of acute hepatitis involves direct hepatocellular injury, leading to cell swelling, necrosis, and apoptosis. The inciting agent may cause oxidative stress, mitochondrial dysfunction, or disruption of cellular membranes. For example, acetaminophen is metabolized to a toxic intermediate (NAPQI) that depletes glutathione and binds to cellular proteins, causing centrilobular necrosis. In leptospirosis, the spirochetes invade the liver and cause damage through immune-mediated mechanisms and direct cytotoxicity. Inflammatory cells, particularly neutrophils and macrophages, infiltrate the liver, releasing cytokines (TNF-α, IL-1, IL-6) that amplify the inflammatory response. This leads to disruption of the hepatic architecture, cholestasis, and impaired synthetic function. If the injury is severe, acute liver failure ensues, characterized by coagulopathy (due to decreased clotting factor synthesis), hypoglycemia, hepatic encephalopathy (due to impaired ammonia detoxification), and jaundice. The liver's regenerative capacity may allow recovery if the animal survives the acute phase, but fibrosis can develop if the insult persists.

Predisposing factors for acute hepatitis include age (young animals may be more susceptible to infectious causes, while older animals may have concurrent diseases), breed (genetic predispositions to copper storage disease or drug sensitivities), and sex (some studies suggest a higher risk in males for leptospirosis). Environmental factors such as exposure to toxins (e.g., aflatoxin-contaminated feed, toxic plants) or infectious agents (e.g., leptospirosis in rural areas) increase risk. Concurrent diseases, such as pancreatitis or inflammatory bowel disease, may predispose to hepatic involvement. Medications, especially those metabolized by the liver, can trigger acute hepatitis, particularly if used at high doses or in animals with pre-existing hepatic dysfunction. Immunosuppression, whether due to disease or drug therapy, may increase susceptibility to infectious causes. Nutritional factors, such as a high-fat diet or rapid weight loss, can predispose to hepatic lipidosis in cats.

Clinical signs of acute hepatitis can range from subtle to severe and may include anorexia, lethargy, vomiting, diarrhea, and weight loss. Jaundice (icterus) is a common finding, particularly in cases with significant cholestasis. Abdominal pain may be present, especially if the liver is enlarged or if there is concurrent pancreatitis. Fever can occur, particularly with infectious causes. In severe cases, signs of acute liver failure may develop, including hypoglycemia (weakness, seizures), coagulopathy (petechiae, ecchymoses, bleeding from venipuncture sites), and hepatic encephalopathy (altered mentation, circling, head pressing, coma). Ascites may develop due to portal hypertension or hypoalbuminemia. In cats, acute hepatitis may present with a more insidious onset, and hepatic lipidosis is a common sequela. Physical examination may reveal hepatomegaly, icteric mucous membranes, and signs of dehydration.

Differential diagnoses for acute hepatitis include: 1) Chronic hepatitis (which may have a more insidious onset and histologic evidence of fibrosis), 2) Hepatic lipidosis (especially in cats, characterized by marked vacuolar change on histology), 3) Cholangiohepatitis (inflammation of bile ducts and liver, often associated with bacterial infection), 4) Gallbladder mucocele (can cause extrahepatic biliary obstruction and secondary hepatic inflammation), 5) Pancreatitis (can cause secondary hepatic inflammation and elevated liver enzymes), 6) Biliary tract obstruction (due to stones, strictures, or neoplasia), 7) Hepatic neoplasia (primary or metastatic), 8) Leptospirosis (can cause acute renal and hepatic failure), 9) Toxin exposure (e.g., xylitol, aflatoxin), and 10) Drug-induced hepatotoxicity. Definitive diagnosis requires a combination of history, clinical signs, laboratory findings, imaging, and histopathology.

The diagnostic approach to acute hepatitis begins with a thorough history and physical examination, with particular attention to potential toxin exposure, medication history, and vaccination status. Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, and urinalysis. If liver enzymes are elevated, further testing includes bile acid stimulation test, coagulation profile (PT, aPTT), and blood ammonia levels. Abdominal ultrasound is recommended to assess liver size, echogenicity, and biliary system. If the cause remains unclear, fine-needle aspiration of the liver may be performed for cytology, but histopathology via biopsy is the gold standard for definitive diagnosis. Additional tests may include serology or PCR for infectious agents (e.g., Leptospira, FIP), toxicology screens, and copper quantification (if copper-associated hepatopathy is suspected). The diagnostic algorithm should be tailored to the individual case, with more invasive tests reserved for cases where the diagnosis is uncertain or the patient is not responding to supportive care.

Laboratory findings in acute hepatitis typically include elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), reflecting hepatocellular injury. Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) may be elevated, especially with cholestasis. Hyperbilirubinemia is common, with conjugated bilirubin predominating. Hypoalbuminemia may occur due to decreased synthesis, and blood urea nitrogen (BUN) may be low due to decreased urea synthesis. Hypoglycemia can occur in severe cases. Coagulation abnormalities, such as prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), may be present due to decreased clotting factor synthesis. Hematologic changes may include leukocytosis or leukopenia, depending on the cause. Urinalysis may reveal bilirubinuria, which can be an early indicator of hyperbilirubinemia. Specific biomarkers such as serum bile acids are elevated in cases of hepatic dysfunction. In cases of leptospirosis, serology (MAT) or PCR can confirm the diagnosis. Liver biopsy may show hepatocellular necrosis, inflammation, and cholestasis.

Abdominal radiography may reveal hepatomegaly, but is often unremarkable. Abdominal ultrasonography is more sensitive and may show an enlarged liver with diffuse or multifocal changes in echogenicity (hypoechoic or hyperechoic), a thickened gallbladder wall, or biliary sludge. Doppler ultrasound can assess hepatic blood flow. In cases of extrahepatic biliary obstruction, dilation of the bile ducts may be seen. Computed tomography (CT) and magnetic resonance imaging (MRI) are rarely needed but may be useful for detecting focal lesions or assessing vascular anomalies. In cases of suspected portosystemic shunts, scintigraphy or CT angiography may be performed. Imaging findings are not specific for acute hepatitis and must be correlated with laboratory and histopathologic findings.

Fine-needle aspiration (FNA) of the liver can be performed for cytologic evaluation, which may show evidence of hepatocellular degeneration, necrosis, and inflammatory cells (neutrophils, lymphocytes, macrophages). However, cytology has limitations and may not accurately reflect the degree of inflammation or fibrosis. Histopathology from a biopsy is the gold standard for diagnosis. In acute hepatitis, histologic findings include hepatocellular swelling, vacuolar degeneration, necrosis (often centrilobular), and infiltration of inflammatory cells. Cholestasis may be evident. Special stains, such as rhodanine for copper, can help identify copper-associated hepatopathy. In cases of leptospirosis, silver stains (e.g., Warthin-Starry) may demonstrate spirochetes. Histopathology also helps differentiate acute hepatitis from chronic hepatitis, which shows fibrosis and piecemeal necrosis.

Treatment of acute hepatitis focuses on eliminating the underlying cause, providing supportive care, and managing complications. If a specific toxin or drug is identified, it should be discontinued. For leptospirosis, appropriate antibiotics (e.g., doxycycline) are indicated. Supportive care includes intravenous fluid therapy with balanced electrolyte solutions to correct dehydration and maintain perfusion. Dextrose may be added to treat hypoglycemia. Nutritional support is crucial, especially in cats, to prevent hepatic lipidosis; a high-quality, easily digestible diet may be recommended, and in some cases, a feeding tube may be necessary. Antiemetics (e.g., maropitant) may be used for vomiting. Hepatoprotectants such as S-adenosylmethionine (SAMe), silymarin, and vitamin E may be beneficial, though evidence is limited. Coagulopathy may require vitamin K1 supplementation or fresh frozen plasma. Hepatic encephalopathy is managed with lactulose and dietary protein restriction. In severe cases, hospitalization and intensive care are required. Surgical intervention is rarely needed, except in cases of extrahepatic biliary obstruction or gallbladder mucocele.

The prognosis for acute hepatitis depends on the underlying cause, severity of liver injury, and promptness of treatment. With appropriate therapy, many animals recover fully, as the liver has a high regenerative capacity. However, mortality rates can be high in cases of acute liver failure, with reported rates of 20-50% in dogs. Negative prognostic indicators include severe coagulopathy, hypoglycemia, hepatic encephalopathy, and marked elevations in bilirubin. Animals that survive the acute phase may develop chronic hepatitis or fibrosis. In cats, acute hepatitis can be complicated by hepatic lipidosis, which carries a guarded prognosis if not treated aggressively. Early diagnosis and treatment improve the chances of a favorable outcome.

Follow-up care for animals with acute hepatitis involves serial monitoring of liver enzymes, bilirubin, and coagulation parameters. Initially, rechecks may be needed every 1-2 weeks, then monthly until values normalize. Repeat abdominal ultrasound may be performed to assess liver size and architecture. If the animal is on hepatoprotectants, dose adjustments may be necessary. Long-term management may include a liver-supportive diet and avoidance of hepatotoxic drugs. In cases of copper-associated hepatopathy, lifelong copper restriction and chelation therapy may be required. Vaccination status should be reviewed, especially for infectious causes like leptospirosis. Owners should be educated on the signs of recurrence and the importance of regular veterinary visits.

Pearls: 1) Always consider leptospirosis in any dog with acute hepatitis and fever, especially if there is a history of exposure to wildlife or water. 2) In cats, acute hepatitis is often associated with hepatic lipidosis; early nutritional support is critical. 3) Coagulation testing should be performed before any invasive procedure, such as liver biopsy. 4) SAMe and vitamin E are commonly used hepatoprotectants with minimal side effects. Pitfalls: 1) Do not use corticosteroids in acute hepatitis unless immune-mediated disease is confirmed, as they can worsen infection or delay healing. 2) Avoid using drugs that are hepatotoxic or require hepatic metabolism (e.g., diazepam, phenobarbital) in animals with acute hepatitis. 3) Do not rely solely on liver enzyme elevations to diagnose acute hepatitis; other causes of elevated enzymes (e.g., muscle injury) should be ruled out. 4) Failure to provide adequate nutritional support in cats can lead to hepatic lipidosis, worsening the prognosis.

Drug protocols for acute hepatitis are based on Plumb's Veterinary Drug Handbook. For leptospirosis: Doxycycline 5-10 mg/kg PO q12h for 14 days, or Ampicillin 20 mg/kg IV q8h for initial therapy. For hepatoprotection: S-adenosylmethionine (SAMe) 20 mg/kg PO q24h on an empty stomach; Silymarin (milk thistle) 20-50 mg/kg PO q8-12h; Vitamin E 10-15 IU/kg PO q24h. For coagulopathy: Vitamin K1 0.5-1.5 mg/kg SC or PO q12h for 3-5 days, or fresh frozen plasma 10-20 ml/kg IV if active bleeding. For hepatic encephalopathy: Lactulose 0.5-1 ml/kg PO q8h, titrated to produce soft stools; Metronidazole 7.5 mg/kg PO q12h (caution in liver disease). For nausea/vomiting: Maropitant 1 mg/kg SC q24h or 2 mg/kg PO q24h; Ondansetron 0.5-1 mg/kg IV q12h. For nutritional support: In cats, a feeding tube (e.g., esophagostomy) may be placed, and a high-protein diet (if no encephalopathy) is recommended. Always adjust dosages for hepatic impairment and monitor for drug interactions.

Evidence-based literature on acute hepatitis in dogs and cats is limited, but several studies have evaluated specific causes and treatments. For leptospirosis, a study by Sykes et al. (2011) reported that doxycycline is effective in eliminating the carrier state. A consensus statement from the ACVIM (2019) on leptospirosis recommends early antibiotic therapy and supportive care. For drug-induced hepatotoxicity, a retrospective study by MacPhail et al. (1998) identified carprofen as a common cause in dogs, with clinical signs appearing within days of administration. A study by Webster et al. (2019) evaluated the use of SAMe in dogs with liver disease and found it may improve survival. In cats, a study by Center (2005) highlighted the importance of nutritional support in hepatic lipidosis, with a reported survival rate of 80% with aggressive feeding. The ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis (2021) provides guidelines that may be extrapolated to acute cases. Overall, there is a lack of large randomized controlled trials, and treatment recommendations are often based on expert opinion and small case series.